Background—Bone marrow CD133-postive (CD133+) cells possess high hematopoietic and
angiogenic capacity. We tested the feasibility, safety, and functional effects of the use of …

Objective—Bone marrow–derived circulating endothelial progenitor cells (EPCs) may
contribute to regeneration of infarcted myocardium and enhance neovascularization …

Background—The existence of circulating endothelial progenitor cells (CEPCs) has
previously been documented. These cells can be mobilized by cytokines and are recruited …

Endothelial dysfunction and cell loss are prominent features in cardiovascular disease.
Endothelial progenitor cells (EPCs) originating from the bone marrow play a significant role …

Endothelial progenitor cells (EPC) predict morbidity and mortality in patients at
cardiovascular risk. Patients with low EPC counts and impaired endothelial colony forming …

Cell-based therapy has emerged as a promising therapeutic tool for treatment of ischemic
cardiovascular disease. Both unselected bone marrow-derived mononuclear cells (BMNCs) …

Exercise is known to improve endothelial function in healthy subjects as well as patients with
cardiovascular disease and this might be partially related to a regeneration of diseased …

Myocyte loss in the ischemically injured mammalian heart often leads to irreversible deficits
in cardiac function. To identify a source of stem cells capable of restoring damaged cardiac …

METHODS Thirty four patients (mean (SEM) age 62.5 (1.7) years) with angiographically
documented stable CAD, and 36 healthy control subjects (mean (SEM) age 53.6 (2.0) years) …

Objectives: Cytokine mobilization of progenitor cells from bone marrow may promote
myocardial neovascularization with relief of ischemia. Background: Patients with coronary …